CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 1, January – April 2024 AFRICA 15 and patients. This eventually showed a reduction in 30-day hospital re-admission rates. The EF did not improve in 2014, but significantly improved in 2015 with the execution of the programme. More outcomes, including mortality rate and cost, would be essential to investigate in future follow ups. We are grateful to all the associated personnel who contributed for the purpose of this research. References 1. Straburzyńska-Migaj E, Kałużna-Oleksy M, Maggioni AP, Grajek S, Opolski G, Ponikowski P, et al. Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population. Arch Med Sci 2015; 11: 743–750. 2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30–41. 3. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2016 Update: A report from the American Heart Association. Circulation 2016; 133: e38–e360. 4. Shehab A, Al-Dabbagh B, Almahmeed W, Bustani N, Nagelkerke N, Yusufali A, et al. Characteristics and in-hospital outcomes of patients with acute coronary syndromes and heart failure in the United Arab Emirates. BMC Res Notes 2012; 5: 534. https://doi.org/10.1186/17560500-5-534 5. Agarwal AK, Venugopalan P, de Bono D. Prevalence and etiology of heart failure in an Arab population. Eur J Heart Fail 2001; 3: 301–305. 6. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012; 60: e44–164. 7. Holmes DR. President’s page: Zeroes, San Jose, Phoenix, Dallas, San Diego. J Am Coll Cardiol 2012; 59: 88–89. 8. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart 2013; 15: 361–362. 9. Milfred-LaForest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor CR, Gattis-Stough W, et al. An opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Card Fail 2013; 19: 354–369. 10. McConnell KJ. Transitions in Care for Congestive-Heart-FailurePatients-Pharmacy-S-Role.pdf. 2015th edn. Colorado: ACCP Updates in Therapeutics® 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course. 11. Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J 2016; 18(suppl_G): G43–52. 12. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Effects of ealapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–1435. 13. Cohn J, Tognoni G. For the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675. 14. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13. 15. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. For the randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717. 16. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al., Investigators P-H and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004. 17. Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ. Can vaccinations improve heart failure outcomes? Contemporary data and future directions. J Am Coll Cardiol Heart Failure 2017; 5(3): 194–203. 18. Joseph J, Stephy PS, James J, Abraham S, Abdullakutty J. Guidelinedirected medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department. Egyptian Heart J 2020; 72(1): 1–8. 19. Nigro SC, Garwood CL, Berlie H, Irons B, Longyhore D, McFarland MS, et al. Clinical pharmacists as key members of the patient-centered medical home: an opinion statement of the Ambulatory Care Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2014; 34: 96–108. 20. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Int Med 2008; 168: 847–854 21. Pellicori P, Cleland JG, Clark AL. Chronic obstructive pulmonary disease and heart failure: a breathless conspiracy. Cardiol Clin 2022; 40(2): 171–182.
RkJQdWJsaXNoZXIy NDIzNzc=